TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15421 · Jan 18

#python#audio#deeplearning#minicpm#python#pytorch#speech#speech_synthesis#text_to_speech#tts#tts_model#voice_cloning VoxCPM is a free, open-source TTS tool that turns text into realistic speech without tokens, creating expressive audio that matches context and clones voices perfectly from just 3-10 seconds of sample. Download VoxCPM1.5 (800M params) from Hugging Face, install via pip, and use simple Python or CLI commands for fast synthesis (RTF 0.15 on RTX 4090) or fine-tuning your own voices. You benefit by easily making natural audiobooks, podcasts, clones, or apps with pro-quality sound—saving time and costs on voice work. https://github.com/OpenBMB/VoxCPM

Results

3 similar posts found

Search: #clinicalstage

当前筛选 #clinicalstage清除筛选
Venture Village Wall 🦄

@venturevillagewall · Post #3534 · 12/20/2024, 09:31 AM

$2.16M Fundraising by Umecrine Umecrine Cognition, a Swedish clinical-stage pharmaceutical firm, has raised $2.16 million to advance its innovative drug development targeting neurological disorders. The funding round took place on December 19, 2024. #UmecrineCognition#Pharmaceuticals#NeurologicalDisorders#Funding#Healthcare#ClinicalStage#Sweden

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3412 · 12/18/2024, 12:11 PM

$60M Funding for Psioxus Psioxus Therapeutics has successfully secured $60M in funding as part of its latest round, scheduled for December 17, 2024. This funding aims to advance its innovative tumor gene therapy platform focused on improving cancer treatment outcomes. #Funding#Cancer#Biotech#Oncology#GeneTherapy#Therapeutics#ClinicalStage#Investment#Healthcare#Psioxus#AkamisBio#Tumor#LifeScience#MedicalResearch#Therapy#Innovative#Impact#Technology#Platform